OncoMatch/Clinical Trials/NCT05107674
A Study of NX-1607 in Adults With Advanced Malignancies
Is NCT05107674 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including NX-1607 and Paclitaxel for ovarian cancer, epithelial.
Treatment: NX-1607 · Paclitaxel — This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-1607 in patients with advanced malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Gastric Cancer
Esophageal Carcinoma
Head and Neck Squamous Cell Carcinoma
Melanoma
Non-Small Cell Lung Carcinoma
Prostate Cancer
Mesothelioma
Triple-Negative Breast Cancer
Breast Carcinoma
Urothelial Carcinoma
Cervical Cancer
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Colorectal Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard treatment options
have received standard treatment options, are not candidates for standard treatment options, or will otherwise be prevented from receiving any standard treatment options
Cannot have received: checkpoint inhibitor (anti-PD-1, anti-PD-L1, cytotoxic T-lymphocyte-associated protein 4)
CPI (anti-PD-1, PD-L1, cytotoxic T-lymphocyte-associated protein 4, etc) within 3 weeks
Cannot have received: autologous or allogeneic stem cell transplant
autologous or allogeneic stem cell transplant within 100 days
Cannot have received: systemic cancer therapy
Exception: unless otherwise specified
prior systemic cancer therapy within 3 weeks or 5 half-lives (whichever is shorter) (unless otherwise specified) (including hormonal therapy except for hormonal prophylaxis for a prior malignancy)
Cannot have received: radiotherapy
prior radiotherapy within 2 weeks
Cannot have received: nitrosoureas
prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks
Cannot have received: antibody-drug conjugate
prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks
Cannot have received: radio-immuno-conjugate therapy
prior systemic therapy with nitrosoureas, antibody-drug conjugate, or radio-immuno-conjugate therapy within 6 weeks
Cannot have received: CAR-T cell therapy
History of CAR-T therapy within 30 days prior to the first dose of NX-1607
Lab requirements
Blood counts
Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters.
Kidney function
Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters.
Liver function
Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters.
Adequate organ and bone marrow function, in the absence of growth factors (with limited exception for DLBCL), as defined by laboratory parameters.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- University of Southern California · Los Angeles, California
- University of California, San Francisco · San Francisco, California
- University of Colorado School of Medicine · Aurora, Colorado
- University of Chicago · Chicago, Illinois
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify